Skip to content
10-Q

Quarterly Report

Keros Therapeutics, Inc. KROS

0001664710-26-000030

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 19.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.63M sh
Shares Diluted Q1 2026 · Mar 31, 2025 41.02M sh
Capex Q1 2026 · Mar 31, 2026 $73K
Capex Q1 2026 · Mar 31, 2025 $565K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.53M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $161.17M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $281.5M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $287.42M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $720.54M
Stockholders Equity Q1 2026 · Mar 31, 2026 $285.63M
Stockholders Equity Q1 2026 · Dec 31, 2025 $303.13M
Stockholders Equity Q1 2026 · Mar 31, 2025 $728.87M
Stockholders Equity Q1 2026 · Dec 31, 2024 $571.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $12.85M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.41M
Total Liabilities Q1 2026 · Mar 31, 2026 $26.66M
Total Liabilities Q1 2026 · Dec 31, 2025 $34.89M
Current Assets Q1 2026 · Mar 31, 2026 $290.68M
Current Assets Q1 2026 · Dec 31, 2025 $315.43M
Total Assets Q1 2026 · Mar 31, 2026 $312.29M
Total Assets Q1 2026 · Dec 31, 2025 $338.02M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.21
Eps Diluted Q1 2026 · Mar 31, 2025 $3.62
Eps Basic Q1 2026 · Mar 31, 2026 −$1.21
Eps Basic Q1 2026 · Mar 31, 2025 $3.66
Sga Expense Q1 2026 · Mar 31, 2026 $10.15M
Sga Expense Q1 2026 · Mar 31, 2025 $10.5M
Rd Expense Q1 2026 · Mar 31, 2026 $16.1M
Rd Expense Q1 2026 · Mar 31, 2025 $48.71M
Net Income Q1 2026 · Mar 31, 2026 −$23.71M
Net Income Q1 2026 · Mar 31, 2025 $148.45M
Operating Income Q1 2026 · Mar 31, 2026 −$25.88M
Operating Income Q1 2026 · Mar 31, 2025 $152.04M
Revenue Q1 2026 · Mar 31, 2026 $367K
Revenue Q1 2026 · Mar 31, 2025 $211.25M
Stock Repurchased Q1 2026 · Oct 20, 2025 $194.4M
Stock Repurchased Q1 2026 · Oct 15, 2025 $180.6M